Related references
Note: Only part of the references are listed.ESC 2022 guidelines on cardio-oncology in collaboration with the European Hematology Association (EHA), European Society of Therapeutic Radiology and Oncology (ESTRO) and International Cardio-Oncology Society (IC- OS) developed by the Cardio-Oncology Task Force of the European Society of Cardiology (ESC)
Alexander R. Lyon et al.
GIORNALE ITALIANO DI CARDIOLOGIA (2023)
Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study
Heather Greenlee et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
Alexander R. Lyon et al.
EUROPEAN HEART JOURNAL (2022)
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Joerg Herrmann
NATURE REVIEWS CARDIOLOGY (2020)
Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases
Helen Strongman et al.
LANCET (2019)
Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors
Talya Salz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Functional status and quality of life among breast cancer survivors with heart failure: results of the Medicare Health Outcomes Survey
Jordan M. Harrison et al.
SUPPORTIVE CARE IN CANCER (2017)
Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
Joerg Herrmann
CURRENT ONCOLOGY REPORTS (2016)
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study
Xavier Pivot et al.
EUROPEAN JOURNAL OF CANCER (2015)
Cardiovascular Disease After Hodgkin Lymphoma Treatment 40-Year Disease Risk
Frederika A. van Nimwegen et al.
JAMA INTERNAL MEDICINE (2015)
Performance of Claims-based Algorithms for Identifying Heart Failure and Cardiomyopathy Among Patients Diagnosed With Breast Cancer
Larry A. Allen et al.
MEDICAL CARE (2014)
Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity
Marzia Lotrionte et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Expert Consensus for Multi-Modality Imaging Evaluation of Cardiovascular Complications of Radiotherapy in Adults: A Report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography
Patrizio Lancellotti et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2013)
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
G. Curigliano et al.
ANNALS OF ONCOLOGY (2012)
Data Resource Profile: The Rochester Epidemiology Project (REP) medical records-linkage system
Jennifer L. St Sauver et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2012)
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
Erin J. Aiello Bowles et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
History of the Rochester Epidemiology Project: Half a Century of Medical Records Linkage in a US Population
Walter A. Rocca et al.
MAYO CLINIC PROCEEDINGS (2012)
Generalizability of Epidemiological Findings and Public Health Decisions: An Illustration From the Rochester Epidemiology Project
Jennifer L. St Sauver et al.
MAYO CLINIC PROCEEDINGS (2012)
Use of a Medical Records Linkage System to Enumerate a Dynamic Population Over Time: The Rochester Epidemiology Project
Jennifer L. St Sauver et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2011)
Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study
Emily Ho et al.
HEART (2010)
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
Michael S. Ewer et al.
NATURE REVIEWS CARDIOLOGY (2010)
Cardiac Toxicity Associated With Anthracycline-Containing Chemotherapy in Older Women With Breast Cancer
Xianglin L. Du et al.
CANCER (2009)
Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management
Edward T. H. Yeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
New insight into epirubicin cardiac toxicity: Competing risks analysis of 1097 breast cancer patients
Marianne Ryberg et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
E Tan-Chiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
